- The new unit will produce 10,000 tonnes of paracetamol annually.
- The facility will be operational by 2023.
- The project is supported by the France Relance programme.
- Sanofi and UPSA are partners in this initiative.
Project Launch
SEQENS has initiated the construction of a new paracetamol production unit in Roussillon, France, in collaboration with Sanofi and UPSA, and supported by the France Relance programme. The unit will have an annual capacity of 10,000 tonnes and is scheduled to be operational by 2023.
Technological and Environmental Advancements
After a year of R&D, SEQENS developed new continuous synthesis processes, significantly reducing the environmental footprint by a factor of 5 to 10 compared to existing units. This innovative approach ensures a high-performance, competitive, and eco-friendly facility.
Strategic Importance
Announced during the health crisis in June 2020, this project aims to strengthen the production of essential active ingredients in France and Europe. It addresses the supply shortages experienced during the crisis and enhances the resilience of the EU's health product manufacturing capabilities.
Location and Infrastructure
The new unit will be built on the Roussillon platform, benefiting from the proximity to SEQENS' pharmaceutical activities and access to shared infrastructures, including low-carbon energy. This site was previously home to a paracetamol production workshop closed by the Rhodia group in 2008.
Government and Industry Support
The project has secured part of its financing through the France Relance programme and long-term commitments from Sanofi and UPSA. The French government emphasizes the importance of investing in domestic production capacities to ensure health sovereignty for the European Union.
